

---

**ABOUT I-MASK+**


---

I-MASK+ PROTOCOL  
 DOWNLOADS & TRANSLATIONS

---

FAQ ON THE USE OF  
 IVERMECTIN IN COVID-19

---

EPIDEMIOLOGIC ANALYSES ON  
 IVERMECTIN IN COVID-19

---

# I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19

In October 2020, the FLCCC Alliance developed a prophylactic and early outpatient combination treatment protocol for COVID-19 called **I-Mask+**. It's centered around **Ivermectin**, a well-known, FDA-approved anti-parasite drug that has been used successfully for more than four decades to treat onchocerciasis "river blindness" and other parasitic diseases. It is one of the safest drugs known. It is on the WHO's list of essential medicines, has been given 3.7 billion times around the globe, and won the Nobel prize for its global and historic impacts in eradicating endemic parasitic infections in many parts of the world. Our medical Discovery of a rapidly growing published medical evidence base demonstrating its unique and highly potent ability to inhibit SARS-CoV-2 replication and to suppress inflammation, prompted our team to use ivermectin for prevention and treatment in all stages of COVID-19.

Our life-saving [MATH+ Hospital Treatment Protocol for COVID-19](#) (available in several languages), created in March 2020, is intended for hospitalized patients, the recently developed **I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19** (this page) is designed for use as a prophylaxis and in early outpatient treatment, for those who test positive for COVID-19. The protocols complement each other, and both are physiologic-based combination treatment regimens developed by leaders in critical care medicine. All the component medicines are FDA-approved, inexpensive, readily available and have been used for decades with well-established safety profiles.

Please download and share our [I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19](#). (It is currently being translated into several languages).

Below are a list of links to our one-page summary of the latest evidence for the protocol, plus videos of FLCCC Alliance doctors discussing the emerging evidence for the use of ivermectin in the prophylaxis and treatment of COVID-19, and a short list of up-to-date studies and clinical trials on this topic.

## *Publications and videos on the use of ivermectin in our I-MASK+ protocol*

---

- [Our comprehensive review of the emerging evidence for Ivermectin use in our I-MASK+ protocol](#) (PDF, continuously updated)
- [A one-page summary of the scientific review on ivermectin above](#) (PDF)
- [Dr. Paul Marik's comprehensive meta-analysis of COVID-19 therapeutics](#) (PDF)
- [An introductory video explaining the review on Ivermectin by Dr. Pierre Kory](#) (Vimeo)
- [Dr. Paul Marik's recent lecture on I-MASK+](#) (YouTube)
- [Invited Grand Rounds Lecture on ivermectin by Pierre Kory](#) (YouTube)

Please also regard Dr. Paul Marik's latest

- [Guide to the management of COVID-19](#) – An overview of the FLCCC Alliance's MATH+ and I-MASK+ protocols (PDF)

## *Recent studies and clinical trials on ivermectin*

---

November 16, 2020 | Egypt

### **Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic**

Elgazzar A, Basma H, Shaimaa Abo Y, Basma H, Mohy H, Hany M (Research Square; 100956)

<https://doi.org/10.21203/rs.3.rs-100956/v2>

November 3, 2020 | India

### **Role of Ivermectin in the prevention of COVID-19 infection among health care workers in India**

A matched case-control study; Behera P, Patro BK, Singh AK, et al. (medRxiv)

<https://doi.org/10.1101/2020.10.29.20222661>

October 27, 2020 | Iraq

### **Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq**

Hashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulmir AS (medRxiv)

<https://doi.org/10.1101/2020.10.26.20219345>

October 22 | Peru

### **Antiviral and anti-inflammatory properties of ivermectin and its potential use in COVID-19**

Portmann-Baracco A, Bryce-Alberti M, Accinelli RA (NCBI/Arch Bronconeumol/ScienceDirect)

<https://dx.doi.org/10.1016%2Fj.arbr.2020.06.006>

October 12, 2020 | USA

### **Use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19**

Rajter J-C, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter J-J (ICON study; Chest)

<https://doi.org/10.1016/j.chest.2020.10.009>

October 2020 | Peru

### **Real-world evidence: The case of Peru. Causality between ivermectin and COVID-19 infection fatality rate**

Juan Chamie (ResearchGate)

[https://www.researchgate.net/publication/344469305\\_Real-World\\_Evidence\\_The\\_Case\\_of\\_Peru\\_Causality\\_between\\_Ivermectin\\_and\\_COVID-19\\_Infection\\_Fatality\\_Rate](https://www.researchgate.net/publication/344469305_Real-World_Evidence_The_Case_of_Peru_Causality_between_Ivermectin_and_COVID-19_Infection_Fatality_Rate)

August 24, 2020 | Bangladesh

### **Clinical trial of ivermectin plus doxycycline for the treatment of COVID-19 infection**

Dr. Reaz Mahmud, Dhaka Medical College (ClinicalTrials.gov; NCT04523831)

<https://clinicaltrials.gov/ct2/show/NCT04523831>

June 11, 2020 | Argentina

### **Usefulness of topical ivermectin and carrageenan to prevent contagion of COVID-19 (IVERCAR)**

Hector E Carvallo, Eurnekian Public Hospital (ClinicalTrials.gov; NCT04425850)

<https://clinicaltrials.gov/ct2/show/NCT04425850>

June 9, 2020 | Egypt

### **Prophylactic Ivermectin in COVID-19 Contacts**

Waheed Shouman, Zagazig University (ClinicalTrials.gov; NCT04422561)

<https://clinicaltrials.gov/ct2/show/NCT04422561>

June 2020 | Australia

### **The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro**

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (Antiviral Res.; 178:104787)

<https://doi.org/10.1016/j.antiviral.2020.104787>

## Follow us



## Contact

### MAILING ADDRESS

FLCCC Alliance  
6006 N Highlands Avenue  
Madison, WI 53705-0000